Skip to main navigation Skip to search Skip to main content

Mitsubishi Tanabe Pharma America Announces Enrollment Completion for Global, Phase 3b Study of RADICAVA ORS® (edaravone) in ALS

Press/Media

Period23 Mar 2023

Media coverage

53

Media coverage